We create clinically validated digital tools that help people with complex conditions, especially cancer and rare diseases, manage medications and the mental health challenges that accompany treatment. Our products include evidence-based companion apps and regulated digital therapies (Software as a Medical Device) that combine cognitive behavioral approaches, patient-centered design, and AI to improve adherence and clinical outcomes.

We partner with pharmaceutical companies to deliver indication-specific therapy companions and digital therapeutics at scale. Our work has included collaborations with Pfizer and other life sciences partners, focusing on measurable behavior change and clinically proven benefit.

Founded in 2018 by John Drakenberg (Psychologist) and Oliver Fleetwood (Theoretical Computational Molecular Biophysicist), Alex Therapeutics has developed a modular platform to accelerate customized product development. The team of 20+ psychologists, engineers, designers, regulatory and market-access experts operates across the EU and US to design, validate and deploy digital health solutions.

For partnerships or demos, contact [email protected].